Hepatic steatosis and Type 2 diabetes: current and future treatment considerations

References

• Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med.346(16), 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology40(6), 1387–1395 (2004).
   PubMed Web of Science ®Google Scholar
• Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol.8(Suppl. 1), S4–S8 (2009).
   PubMed Web of Science ®Google Scholar
• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med.363(14), 1341–1350 (2010).
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two ‘hits’? Gastroenterology114(4), 842–845 (1998).
   PubMed Web of Science ®Google Scholar
• De Bruyne RM, Fitzpatrick E, Dhawan A. Fatty liver disease in children: eat now pay later. Hepatol. Int.4(1), 375–385 (2010).
   PubMedGoogle Scholar
• Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of Type 2 diabetes. Curr. Diab. Rep.10(4), 306–315 (2010).
   PubMed Web of Science ®Google Scholar
• Caserta CA, Pendino GM, Amante A et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am. J. Epidemiol.171(11), 1195–1202 (2010).
   PubMed Web of Science ®Google Scholar
• Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. Dig. Dis. Sci.56(1), 35–45 (2010).
   PubMedGoogle Scholar
• Targher G, Bertolini L, Rodella S et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabetes Care30(8), 2119–2121 (2007).
   PubMed Web of Science ®Google Scholar
• Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann. Intern. Med.111(6), 473–478 (1989).
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes. Rev.11(6), 430–445 (2010).
   PubMed Web of Science ®Google Scholar
• Bohte AE, Van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and (1)H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur. Radil.21(1), 87–97 (2011).
   PubMed Web of Science ®Google Scholar
• Yoneda M, Fujita K, Inamori M, Tamano M, Hiriishi H, Nakajima A. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut56(9), 1330–1331 (2007).
   PubMed Web of Science ®Google Scholar
• Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Non invasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J. Gastroenterol.16(38), 4784–4791 (2010).
   PubMedGoogle Scholar
• Tabuchi M, Tomioka K, Kawakami T et al. Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD). J. Nutr. Sci. Vitaminol.56(5), 271–278 (2010).
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Dolar E, Ulukaya E et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J. Gastroenterol.13(6), 837–844 (2007).
   PubMed Web of Science ®Google Scholar
• Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology46(1), 32–36 (2007).
   PubMed Web of Science ®Google Scholar
• Mcpherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut59(9), 1265–1269 (2010).
   PubMed Web of Science ®Google Scholar
• Sato F, Tamura Y, Watada H et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J. Clin. Endocrinol. Metab.92(8), 3326–3329 (2007).
   PubMedGoogle Scholar
• Vitola BE, Deivanayagam S, Stein RI et al. Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity17(9), 1744–1748 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson NA, Sachinwalla T, Walton DW et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology50(4), 1105–1112 (2009).
   PubMed Web of Science ®Google Scholar
• St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology50(1), 68–76 (2009).
   PubMed Web of Science ®Google Scholar
• Alam S, Stolinski M, Pentecost C et al. The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in Type 2 diabetes. J. Clin. Endocrinol. Metab.89(2), 688–694 (2004).
   PubMed Web of Science ®Google Scholar
• Lazo M, Solga SF, Horska A et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with Type 2 diabetes. Diabetes Care33(10), 2156–2163 (2010).
   PubMed Web of Science ®Google Scholar
• Furuya CK Jr, De Oliveira CP, De Mello ES et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J. Gastroenterol. Hepatol.22(4), 510–514 (2007).
   PubMed Web of Science ®Google Scholar
• Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig. Dis.28(1), 274–279 (2010).
   PubMed Web of Science ®Google Scholar
• Bell LN, Temm CJ, Saxena R et al. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann. Surg.251(6), 1041–1048 (2010).
   PubMed Web of Science ®Google Scholar
• Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol.12(2), 224–229 (1991).
   PubMed Web of Science ®Google Scholar
• Haukeland JW, Konopski Z, Eggesbo HB et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand. J. Gastroenterol.44(7), 853–860 (2009).
   PubMed Web of Science ®Google Scholar
• Tock L, Damaso AR, De Piano A et al. Long-term effects of metformin and lifestyle modification on nonalcoholic fatty liver disease obese adolescents. J. Obes.pii, 831901 (2010).
   Google Scholar
• Cone CJ, Bachyrycz AM, Murata GH. Hepatotoxicity associated with metformin therapy in treatment of Type 2 diabetes mellitus with nonalcoholic fatty liver disease. Ann. Pharmacother.44(10), 1655–1659 (2010).
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol.100(5), 1082–1090 (2005).
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Bernhardt C et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology51(2), 445–453 (2010).
   PubMed Web of Science ®Google Scholar
• Juurinen L, Kotronen A, Graner M, Yki-Jarvinen H. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with Type 2 diabetes requiring high insulin doses. J. Clin. Endocrinol. Metab.93(1), 118–124 (2008).
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med.355(22), 2297–2307 (2006).
   PubMed Web of Science ®Google Scholar
• Aithal GP, Thomas JA, Kaye PV et al.Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology135(4), 1176–1184 (2008).
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med.362(18), 1675–1685 (2010).
   PubMed Web of Science ®Google Scholar
• Argo CK, Iezzoni JC, Al-Osaimi AM, Caldwell SH. Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? J. Clin. Gastroenterol.43(6), 565–568 (2009).
   PubMed Web of Science ®Google Scholar
• Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with Type 2 diabetes. J. Diabetes Complications21(3), 137–142 (2007).
   PubMed Web of Science ®Google Scholar
• Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J. Clin. Gastroenterol.43(10), 990–994 (2009).
   PubMed Web of Science ®Google Scholar
• Yoshida M. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment. Curr. Vasc. Pharmacol.9(1), 121–123 (2011).
   PubMedGoogle Scholar
• Park H, Shima T, Yamaguchi K et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J. Gastroenterol.46(1), 101–107 (2011).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology39(3), 770–778 (2004).
   PubMed Web of Science ®Google Scholar
• Leuschner UF, Lindenthal B, Herrmann G et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology52(2), 472–479 (2010).
   PubMed Web of Science ®Google Scholar
• Ratziu V, De Ledinghen V, Oberti F et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J. Hepatol. DOI: 10.1016/j.jhep.2010.08.030 (2010) (Epub ahead of print).
   Google Scholar
• Dufour JF, Oneta CM, Gonvers JJ et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol.4(12), 1537–1543 (2006).
   PubMed Web of Science ®Google Scholar
• Vajro P, Mandato C, Franzese A et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J. Pediatr. Gastroenterol. Nutr.38(1), 48–55 (2004).
   PubMed Web of Science ®Google Scholar
• Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol.4, 6 (2005).
   PubMed Web of Science ®Google Scholar
• Yokohama S, Tokusashi Y, Nakamura K et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J. Gastroenterol.12(2), 322–326 (2006).
   PubMed Web of Science ®Google Scholar
• Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J. Gastrointestin. Liver Dis.16(1), 39–46 (2007).
   PubMed Web of Science ®Google Scholar
• Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol.15(8), 942–954 (2009).
   PubMed Web of Science ®Google Scholar
• Mennigen R, Nolte K, Rijcken E et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol.296(5), G1140–G1149 (2009).
   PubMed Web of Science ®Google Scholar
• Loguercio C, Federico A, Tuccillo C et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol.39(6), 540–543 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol.51(2), 380–388 (2009).
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet368(9548), 1696–1705 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta NA, Mells J, Dunham RM et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology51(5), 1584–1592 (2010).
   PubMed Web of Science ®Google Scholar
• Tushuizen ME, Bunck MC, Pouwels PJ, Van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int.26(8), 1015–1017 (2006).
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Falahati A, Braun OO, Schmidt WE, Gough S, Newsome PN. High prevalence of advanced NAFLD in Type 2 diabetic patients with normal liver enzymes and effect of liraglutide on NAFLD: meta-analysis of the LEAD program. Diabetologia1552-P (2010).
   Google Scholar